Fox Run Management L.L.C. Makes New Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Fox Run Management L.L.C. acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 18,526 shares of the company's stock, valued at approximately $688,000.

Several other large investors have also recently made changes to their positions in AMPH. Quest Partners LLC increased its holdings in Amphastar Pharmaceuticals by 74.4% during the third quarter. Quest Partners LLC now owns 7,586 shares of the company's stock worth $368,000 after buying an additional 3,237 shares during the last quarter. Intech Investment Management LLC grew its holdings in Amphastar Pharmaceuticals by 21.9% during the third quarter. Intech Investment Management LLC now owns 12,989 shares of the company's stock valued at $630,000 after purchasing an additional 2,331 shares during the period. Algert Global LLC purchased a new stake in Amphastar Pharmaceuticals in the third quarter worth $3,217,000. BNP Paribas Financial Markets raised its stake in shares of Amphastar Pharmaceuticals by 59.6% in the third quarter. BNP Paribas Financial Markets now owns 94,466 shares of the company's stock valued at $4,584,000 after buying an additional 35,284 shares during the period. Finally, Glenmede Trust Co. NA lifted its position in shares of Amphastar Pharmaceuticals by 145.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 37,884 shares of the company's stock valued at $1,839,000 after buying an additional 22,439 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday.

Remove Ads

Insider Buying and Selling

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH traded down $0.07 during mid-day trading on Tuesday, reaching $28.39. The stock had a trading volume of 713,226 shares, compared to its average volume of 427,720. Amphastar Pharmaceuticals, Inc. has a one year low of $25.89 and a one year high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a 50 day moving average price of $31.72 and a two-hundred day moving average price of $40.36. The stock has a market capitalization of $1.35 billion, a P/E ratio of 9.46, a P/E/G ratio of 2.19 and a beta of 0.77.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.